Top Suppliers:I want be here




127-07-1

127-07-1 structure
127-07-1 structure
  • Name: Hydroxyurea
  • Chemical Name: hydroxyurea
  • CAS Number: 127-07-1
  • Molecular Formula: CH4N2O2
  • Molecular Weight: 76.055
  • Catalog: Biochemical Inhibitor Immune inhibitor
  • Create Date: 2018-02-05 08:00:00
  • Modify Date: 2024-01-01 17:46:32
  • Hydroxyurea is a cell apoptosis inducer that inhibitDNA synthesis through inhibition of ribonucleotide reductase.

Name hydroxyurea
Synonyms hydroxycarbamide
HYDROXYUREA (HYDROXYCARBAMIDE)
HYDROXYUREA 127-07-1
Hydroxyurea
Droxia
HYDROXYCARBAMIDE, BP STANDARD
HYDROXYHARNSTOFF
amino-hydroxamic acid
Hydrea
HYDROXYHARNSTOFF(HYDROXYUREA)
1-hydroxyure
hydroxyl urea
Hydroxy urea
HYDROXYCARBAMIDE (HYDROXYUREA)
MFCD00007943
Urea, N-hydroxy-
Onco-carbide
Oxyurea
N-HYDROXYUREA
EINECS 204-821-7
Litalir
1-Hydroxyurea
Biosupressin
hydroxyure
Description Hydroxyurea is a cell apoptosis inducer that inhibitDNA synthesis through inhibition of ribonucleotide reductase.
Related Catalog
In Vitro Hydroxyurea is used in a number of myeloproliferative, neoplastic, HIV, and non-hematological diseases[1]. Treatment of cells in primary culture with 30 μM hydroxyurea for 96 hours significantly increases the fractional HbF content. The Gγ: Aγ-globin mRNA is induced 0.30- to 8-fold in vitro[2]. Hydroxyurea has been shown to block HIV-1 reverse transcription and/or replication in quiescent peripheral blood mononuclear cells and macrophages[3].
In Vivo Hydroxyurea therapy producs consistent reductions in WBC and ANC without improvement in anemia over 17 weeks. Hydroxyurea at 50mg/kg produces a reduced white blood cell count, absolute neutrophil count and no improvement in anemia compared to vehicle treated sickle cell mice[4].
Animal Admin Mice: To determine whether hydroxyurea would improve anemia and/or prevent or diminish the development of organ damage in the absence of HbF induction, hydroxyurea, at doses of 25 mg/kg, 50 mg/kg, and 100 mg/kg, or vehicle is administered five days per week to SCD mice[4].
References

[1]. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76(1):24-31.

[2]. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33(12):1486-92.

[3]. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7.

[4]. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95(9):1599-603.

Density 1.5±0.1 g/cm3
Boiling Point 222.1±23.0 °C at 760 mmHg
Melting Point 135-140 °C
Molecular Formula CH4N2O2
Molecular Weight 76.055
Flash Point 88.1±22.6 °C
Exact Mass 76.027275
PSA 75.35000
LogP -1.80
Vapour Pressure 0.0±1.0 mmHg at 25°C
Index of Refraction 1.501
Storage condition 2-8°C
Water Solubility soluble
Symbol GHS08
GHS08
Signal Word Danger
Hazard Statements H340-H361
Precautionary Statements P201-P280-P308 + P313
Personal Protective Equipment Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
Hazard Codes T:Toxic
Risk Phrases R46;R61
Safety Phrases S53-S36/37-S45
RIDADR 2811
WGK Germany 3
RTECS YT4900000
Packaging Group III
HS Code 2928000090
HS Code 2924199090
Summary 2924199090. other acyclic amides (including acyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%